FLAG Therapeutics
FLAG Therapeutics, Inc., headquartered in Raleigh, North Carolina, is a near-term clinical stage biotechnology company focused on developing novel small molecule therapeutics for difficult-to-treat cancers with significant unmet medical needs in adults and children. The company leverages three proprietary drug discovery platforms to create water-soluble, multi-acting small molecules that target, bind, and kill cancer cells through established mechanisms. Their lead candidate, FLAG-003, targets Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM) and is on track to enter Phase 1/2 clinical trials in early 2025. The pipeline also includes candidates for triple negative breast cancer, ovarian cancer, mesothelioma, and pancreatic cancer. FLAG Therapeutics holds a robust intellectual property portfolio with over 100 issued patents and 30 pending applications, and benefits from orphan drug and pediatric designations that provide market exclusivity. The company operates under an exclusive worldwide licensing agreement with Duquesne University, utilizing AI and computer modeling in drug discovery. FLAG Therapeutics aims for first product approval within 3 to 5 years, focusing on superior efficacy and safety compared to standard care.
FLAG Therapeutics
FLAG Therapeutics, Inc., headquartered in Raleigh, North Carolina, is a near-term clinical stage biotechnology company focused on developing novel small molecule therapeutics for difficult-to-treat cancers with significant unmet medical needs in adults and children. The company leverages three proprietary drug discovery platforms to create water-soluble, multi-acting small molecules that target, bind, and kill cancer cells through established mechanisms. Their lead candidate, FLAG-003, targets Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM) and is on track to enter Phase 1/2 clinical trials in early 2025. The pipeline also includes candidates for triple negative breast cancer, ovarian cancer, mesothelioma, and pancreatic cancer. FLAG Therapeutics holds a robust intellectual property portfolio with over 100 issued patents and 30 pending applications, and benefits from orphan drug and pediatric designations that provide market exclusivity. The company operates under an exclusive worldwide licensing agreement with Duquesne University, utilizing AI and computer modeling in drug discovery. FLAG Therapeutics aims for first product approval within 3 to 5 years, focusing on superior efficacy and safety compared to standard care.